Healthy Living Tips

FDA Approves Yeztugo (Lenacapavir), Twice-a-Year Shot for HIV Prevention

FDA Approves Yeztugo (Lenacapavir), Twice-a-Year Shot for HIV Prevention

People at risk of contracting HIV through sexual contact have a groundbreaking new option to protect themselves: The U.S. Food and Drug Administration (FDA) approved Yeztugo (lenacapavir), the first and only twice-yearly injectable HIV prevention medication for adults and adolescents who weigh at least 77 pounds. Studies have shown the new drug to be more than 99.9 percent effective at preventing HIV.

Yeztugo offers an alternative to the current regimens available for PrEP (pre-exposure prophylaxis) that people use to prevent HIV, in the form of daily pills or every-other-month injections.

The twice-a-year formulation and the approval are both “really, really exciting,” says

Matthew Hamill, MBChB, PhD, an associate professor of medicine and infectious disease doctor at Johns Hopkins Medicine in Baltimore.

Leave a Reply

Your email address will not be published. Required fields are marked *